Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Abstract: The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.

Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Abstract: The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.

Abstract: The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions.

Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).

Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.

Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).

Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.

Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Abstract: The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.

Abstract: The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).

Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Abstract: The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions.